Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

Bavarian Nordic initiates clinical trials of mpox vaccine in infants and pregnant women: Copenhagen, Denmark Saturday, June 28, 2025, 12:00 Hrs [IST] Bavarian Nordic A/S, a global ...

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.

Bavarian Nordic produces one of the only vaccines for mpox and its shots are the only ones licensed for the disease in the U.S. and European Union.

Looking ahead to the rest of the year, Bavarian Nordic aims to grow earnings some 26% to 30% over that same span. As for what could be next in the company’s travel health portfolio, Bavarian ...

Bavarian Nordic is also sponsoring a trial (NCT06549530) of MVA-BN in children aged 2-11 years, with topline data anticipated in Q3 2025. Jynneos is the only non-replicating mpox vaccine approved ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...